Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients

Documenti analoghi

• “Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
  di: Shoshana Burke, et al.
  Pubblicazione: (2025)
• Comparing functional and genomic‐based precision medicine in blood cancer patients
  di: Lukas Kazianka, et al.
  Pubblicazione: (2025)
• Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
  di: Fabio Efficace, et al.
  Pubblicazione: (2024)
• Correction to “Comparing functional and genomic‐based precision medicine in blood cancer patients”
  Pubblicazione: (2025)
• Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML
  di: Uta Oelschlaegel, et al.
  Pubblicazione: (2025)